• Most Popular
  • Most Shared

Novartis says Japan study shows Diovan benefits

Fri Apr 27, 2007 3:07am EDT

Stocks

   

ZURICH, April 27 (Reuters) - Novartis AG's (NOVN.VX) blood pressure drug Diovan cut incidence of strokes and cardiovascular events by about 40 percent in an independent Japanese study, the Swiss drugmaker said on Friday.

New findings from the Jikei Heart Study, published Friday in The Lancet, showed Diovan produced a 39 percent reduction in cardiovascular events and a 40 percent cut in strokes.

The study compared Diovan when added to a conventional non-angiotensin receptor blocker (ARB) versus the non-ARB therapy alone.

The Jikei study involved some 3,000 people aged 20 to 79 with high blood pressure, ischemic heart disease or congestive heart failure.

((Reporting by Sam Cage, editing by Erica Billingham;

Email: zurich.newsroom@reuters.com

Reuters Messaging:

sam.cage.reuters.com@reuters.net

Telephone: +41 (0) 44 631 7457)) Keywords: NOVARTIS DIOVAN/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL27381872


More from Reuters

Photo

Tech solutions to climate change

Experts say there is no single answer to solving global warming, but a handful of technologies could be promising. Check out some of the candidates and join the debate.  Full Article 

    Climate conference
    Onlookers gather outside the historic Federal Hall where U.S. President Barack Obama is speaking in the heart of Wall Street in New York September 14, 2009. REUTERS/Larry Downing

    One step closer to reform

    The House of Representatives approved the biggest changes in financial regulation since the Great Depression, marking a win for the Obama administration and congressional Democrats.  Full Article 

    Regulatory News
    The share price index DAX board is seen in front of an emergency exit sign at Frankfurt's stock exchange, October 8, 2008. REUTERS/Kai Pfaffenbach

    "Deflation is with us"

    Fear of the market abyss has faded for investors, but another fear is lurking on the horizon, if not already here.  Full Article 

    Investment Outlook Summit